| Autor: |
Hu, L.-Y., Ryder, T. R., Rafferty, M. F., Feng, M. R., Lotarski, S. M., Rock, D. M., Sinz, M., Stoehr, S. J., Taylor, C. P., Weber, M. L., Bowersox, S. S., Miljanich, G. P., Millerman, E., Wang, Y.-X., Szoke, B. G. |
| Zdroj: |
Journal of Medicinal Chemistry; October 7, 1999, Vol. 42 Issue: 20 p4239-4249, 11p |
| Abstrakt: |
In this article, the rationale for the design, synthesis, and biological evaluation of a series of N-type voltage-sensitive calcium channel (VSCC) blockers is described. N-Type VSCC blockers, such as ziconotide, have shown utility in several models of stroke and pain. Modification of the previously reported lead, 1a, led to several 4-(4-benzyloxylphenyl)piperidine structures with potent in vitro and in vivo activities. In this series, the most interesting compound, (S)-2-amino-1-{4-[(4-benzyloxy-phenyl)-(3-methyl-but-2-enyl)-amino]-piperidin-1-yl}-4-methyl-pentan-1-one (11), blocked N-type calcium channels (IC50 = 0.67 μM in the IMR32 assay) and was efficacious in the audiogenic DBA/2 seizure mouse model (ED50 = 6 mg/kg, iv) as well as the antiwrithing model (ED50 = 6 mg/kg, iv). Whole-cell voltage-clamp electrophysiology experiments demonstrated that compound 11 blocked N-type Ca2+ channels and Na+ channels in superior cervical ganglion neurons at similar concentrations. Compound 11, which showed superior in vivo efficacy, stands out as an interesting lead for further development of neurotherapeutic agents in this series. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
